Literature DB >> 2365462

Serum antibody response in adult volunteers elicited by injection of Streptococcus pneumoniae type 12F polysaccharide alone or conjugated to diphtheria toxoid.

A Fattom1, C Lue, S C Szu, J Mestecky, G Schiffman, D Bryla, W F Vann, D Watson, L M Kimzey, J B Robbins.   

Abstract

Conjugates of an uronic acid-containing capsular polysaccharide (CP), pneumococcous type 12F (Pn12F) bound to diphtheria toxoid (DT), were studied for safety and immunogenicity in adult volunteers. In mice, these conjugates, prepared with the same lot of DT and Pn12F-40234-006, a homogenous CP of high molecular weight, or Pn12-812408, a polydisperse CP with lower-molecular-weight material, were more immunogenic than the Pn12F alone and had T-cell dependent properties (A. Fattom, W. F. Vann, S.C. Szu, A. Sutton, X. Li, B. Bryla, G. Schiffman, J. B. Robbins, and R. Schneerson, Infect. Immun. 56:2292-2298, 1988). Adult volunteers, randomized into three groups, were injected either with one of these two conjugates or with Pnu-Imune, the 23 valent pneumococcus vaccine containing 25 micrograms of Pn12F as one of its components. Volunteers were injected two times, 4 weeks apart, with the Pn12F-DT conjugates and once with the Pnu-Imune. Side reactions following injection of the conjugates of Pnu-Imune were mild and short-lived. At 4 weeks and at 7 months after the first injection, higher levels of Pn12F antibodies were found in the volunteers injected with the conjugates than in the Pnu-Imune group (P less than 0.001). The conjugate prepared with the higher-molecular-weight Pn12F elicited higher levels of antibodies than the conjugate prepared with a lower-molecular-weight Pn12F preparation (P = 0.05). Both conjugates elicited about a 13-fold rise in DT antibodies.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2365462      PMCID: PMC258813          DOI: 10.1128/iai.58.7.2309-2312.1990

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  27 in total

1.  Impaired antibody response to pneumococcal vaccine after treatment for Hodgkin's disease.

Authors:  G R Siber; S A Weitzman; A C Aisenberg; H J Weinstein; G Schiffman
Journal:  N Engl J Med       Date:  1978-08-31       Impact factor: 91.245

Review 2.  Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future.

Authors:  J B Robbins
Journal:  Immunochemistry       Date:  1978-11

3.  Pneumococcal vaccination of recipients of bone marrow transplants.

Authors:  D J Winston; W G Ho; G Schiffman; R E Champlin; S A Feig; R P Gale
Journal:  Arch Intern Med       Date:  1983-09

4.  Humoral immune response of kidney transplant recipients to pneumococcal vaccine.

Authors:  T J Marrie; G Schiffman; R Bortolussi; C Field; A Whalen
Journal:  Proc Soc Exp Biol Med       Date:  1981-05

Review 5.  Streptococcus pneumoniae polysaccharide vaccine: age and dose responses, safety, persistence of antibody, revaccination, and simultaneous administration of pneumococcal and influenza vaccines.

Authors:  M R Hilleman; A J Carlson; A A McLean; P P Vella; R E Weibel; A F Woodhour
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

6.  A radioimmunoassay for immunologic phenomena in pneumococcal disease and for the antibody response to pneumococcal vaccines. I. Method for the radioimmunoassay of anticapsular antibodies and comparison with other techniques.

Authors:  G Schiffman; R M Douglas; M J Bonner; M Robbins; R Austrian
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

7.  Comparison of the induction of immunoglobulin M and G antibodies in mice with purified pneumococcal type 3 and meningococcal group C polysaccharides and their protein conjugates.

Authors:  E C Beuvery; F van Rossum; J Nagel
Journal:  Infect Immun       Date:  1982-07       Impact factor: 3.441

Review 8.  Assessment of the antibody response to pneumococcal vaccine in high-risk populations.

Authors:  S H Landesman; G Schiffman
Journal:  Rev Infect Dis       Date:  1981 Mar-Apr

9.  Synthesis and immunologic properties in mice of vaccines composed of Staphylococcus aureus type 5 and type 8 capsular polysaccharides conjugated to Pseudomonas aeruginosa exotoxin A.

Authors:  A Fattom; R Schneerson; S C Szu; W F Vann; J Shiloach; W W Karakawa; J B Robbins
Journal:  Infect Immun       Date:  1990-07       Impact factor: 3.609

10.  Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates.

Authors:  R Schneerson; O Barrera; A Sutton; J B Robbins
Journal:  J Exp Med       Date:  1980-08-01       Impact factor: 14.307

View more
  16 in total

1.  Synthesis, characterization, and some immunological properties of conjugates composed of the detoxified lipopolysaccharide of Vibrio cholerae O1 serotype Inaba bound to cholera toxin.

Authors:  R K Gupta; S C Szu; R A Finkelstein; J B Robbins
Journal:  Infect Immun       Date:  1992-08       Impact factor: 3.441

2.  Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide.

Authors:  J C Paton; R A Lock; C J Lee; J P Li; A M Berry; T J Mitchell; P W Andrew; D Hansman; G J Boulnois
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

3.  The pneumococcus: host-organism interactions and their implications for immunotherapy and immunoprophylaxis.

Authors:  F E Perry; J R Catterall
Journal:  Thorax       Date:  1994-10       Impact factor: 9.139

4.  Enzyme immunoassay for detection of immunoglobulin G (IgG), IgM, and IgA antibodies against type 6B pneumococcal capsular polysaccharide and cell wall C polysaccharide in chinchilla serum.

Authors:  M Koskela; M Harris; G S Giebink
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

5.  Characterization of a human monoclonal immunoglobulin M (IgM) antibody (IgMBEN) specific for Vi capsular polysaccharide of Salmonella typhi.

Authors:  J Liao; K G Nickerson; S Bystricky; J B Robbins; R Schneerson; S C Szu; E A Kabat
Journal:  Infect Immun       Date:  1995-11       Impact factor: 3.441

6.  Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.

Authors:  Zhigang Jin; Chiayung Chu; John B Robbins; Rachel Schneerson
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

7.  Comparisons of standard curve-fitting methods to quantitate Neisseria meningitidis group A polysaccharide antibody levels by enzyme-linked immunosorbent assay.

Authors:  B D Plikaytis; S H Turner; L L Gheesling; G M Carlone
Journal:  J Clin Microbiol       Date:  1991-07       Impact factor: 5.948

Review 8.  Pneumococcal virulence factors and host immune responses to them.

Authors:  D A Watson; D M Musher; J Verhoef
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-06       Impact factor: 3.267

9.  Synthesis of a conjugate vaccine composed of pneumococcus type 14 capsular polysaccharide bound to pertussis toxin.

Authors:  R Schneerson; L Levi; J B Robbins; D M Bryla; G Schiffman; T Lagergard
Journal:  Infect Immun       Date:  1992-09       Impact factor: 3.441

10.  Mucosal immunogenicity of polysaccharides conjugated to a peptide or multiple-antigen peptide containing T- and B-cell epitopes.

Authors:  E Lett; C Klopfenstein; J P Klein; M Schöller; D Wachsmann
Journal:  Infect Immun       Date:  1995-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.